Broad Institute of MIT and Harvard was launched in 2004 to improve human health by using genomics to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies. The institute was founded to seize the opportunity that arose from the Human Genome Project --the international effort that successfully deciphered the entire human genetic code. Despite that accomplishment, scientists knew they still lacked a clear understanding of the genetic basis of disease, and how to translate that understanding into more effective prevention, diagnosis, and treatment.
Immune checkpoint inhibitors help patients’ immune systems fight cancer, but many patients develop resistance to these inhibitors.
Check out our latest newsletter on tracking COVID-19 mutations, supporting COVID-19 pooled testing in schools, and more: broad.io/ Newsletter030821
In this week's #BroadResearchRo undup: Molecular roots of COVID-19 susceptibility, cells' nutrients affect CRISPR screens, understanding prostate cancer resistance, and more.
The Human Cell Atlas Lung Biological Network reports single-cell meta-analysis suggesting biological roots of COVID-19 risk factors; shares resource for studies of COVID-19 biology and therapies.
TODAY! Join us virtually from 2 - 3 pm ET for our 6th annual event showcasing rare disease research, "Focus on rare disease: Prime time — gene therapy for rare disorders." Register and stream the talk at https:// broad.io/ WatchRareDisease 21.
Watch the first Broad Equity in Biomedicine seminar series talk by @sandrasoojinlee Chief, Division of Ethics… https://t.co/m0dkPwNf8o
Similar Businesses
